Details for New Drug Application (NDA): 019425
✉ Email this page to a colleague
The generic ingredient in TRANDATE is hydrochlorothiazide; labetalol hydrochloride. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; labetalol hydrochloride profile page.
Summary for 019425
Tradename: | TRANDATE |
Applicant: | Sebela Ireland Ltd |
Ingredient: | labetalol hydrochloride |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 019425
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Dec 31, 1985 | TE: | RLD: | Yes |
Expired US Patents for NDA 019425
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sebela Ireland Ltd | TRANDATE | labetalol hydrochloride | INJECTABLE;INJECTION | 019425-001 | Dec 31, 1985 | ⤷ Sign Up | ⤷ Sign Up |
Sebela Ireland Ltd | TRANDATE | labetalol hydrochloride | INJECTABLE;INJECTION | 019425-001 | Dec 31, 1985 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription